Log in
OTCMKTS:CADMF

Chemesis International Stock Forecast, Price & News

$0.29
-0.01 (-3.33 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.29
Now: $0.29
$0.32
50-Day Range
$0.25
MA: $0.33
$0.42
52-Week Range
$0.22
Now: $0.29
$1.59
Volume11,626 shs
Average Volume60,437 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Chemesis International Inc., together with its subsidiaries, cultivates, manufactures, distributes, and retails cannabis products in California, Puerto Rico, and Colombia. It offers various types of extractions, formulations, and products specializing in BHO extraction, alcohol extraction, and CO2 extraction. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.78 out of 5 stars


Industry, Sector and Symbol

Industry Industrial Metals & Minerals
Sub-IndustryN/A
Current SymbolOTCMKTS:CADMF
CUSIPN/A
CIKN/A
Phone(604) 398-3378
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable
$0.29
-0.01 (-3.33 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CADMF News and Ratings via Email

Sign-up to receive the latest news and ratings for CADMF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Chemesis International (OTCMKTS:CADMF) Frequently Asked Questions

How has Chemesis International's stock price been impacted by COVID-19?

Chemesis International's stock was trading at $0.4969 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CADMF stock has decreased by 41.6% and is now trading at $0.29.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Chemesis International?

Wall Street analysts have given Chemesis International a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Chemesis International wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Chemesis International?

Chemesis International saw a drop in short interest during the month of October. As of October 30th, there was short interest totaling 2,100 shares, a drop of 19.2% from the October 15th total of 2,600 shares. Based on an average trading volume of 67,700 shares, the short-interest ratio is currently 0.0 days.
View Chemesis International's Short Interest
.

Who are some of Chemesis International's key competitors?

Who are Chemesis International's key executives?

Chemesis International's management team includes the following people:
  • Mr. Edgar Montero, CEO & Director
  • Mr. Eli Seamus-Sweet Dusenbury C.A., CPA, CPA, CA, Chief Financial Officer (Age 38)
  • Mr. Josh Rosenberg, Pres & Director
  • Mr. Shaun Dale, VP of Operations (Age 43)
  • Dr. Joshua Hartsel, Chief Science Officer
  • Mr. Thomas J. Gingerich, Controller (Age 59)

What is Chemesis International's stock symbol?

Chemesis International trades on the OTCMKTS under the ticker symbol "CADMF."

How do I buy shares of Chemesis International?

Shares of CADMF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Chemesis International's stock price today?

One share of CADMF stock can currently be purchased for approximately $0.29.

What is Chemesis International's official website?

The official website for Chemesis International is www.chemesis.com.

How can I contact Chemesis International?

The company can be reached via phone at (604) 398-3378.

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.